About Us


Revive Therapeutics Ltd. is a publicly-traded company listed on the OTCQB: RVVTF in the U.S. and the TSX Venture: RVV in Canada.

 

Revive's lead product is in the treatment for acute gout flares, which completed a Phase 2a study in the U.S.

 

Also, Revive is advancing developments in rare diseases such as, Cystinuria, which was granted FDA Orphan Drug Status, Wilson's disease and Rett syndrome (partnered with Rettsyndrome.org).

Read more

news

News

June 20, 2016

Revive Announces Completion of Rights Offering for Gross Proceeds of $844,693 to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

Read more
May 30, 2016

Announces $1,500,000 Best-Efforts Non-Brokered Private Placement

Read more
May 16, 2016

Revive Announces Rights Offering to Fund the Clinical Development of Bucillamine for the Treatment of Cystinuria

Read more
May 10, 2016

Revive Therapeutics Provides Clinical and Corporate Update

Read more
May 09, 2016

Revive Therapeutics Announces Results for the Three and Nine Months Ended March 31, 2016

Read more
Newsletter
Corporate presentation

 

Presentation

June 2016

BioNap Article